CytomX Therapeutics Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • CytomX Therapeutics's estimated annual revenue is currently $66.2M per year.(i)
  • CytomX Therapeutics received $70.0M in venture funding in June 2015.
  • CytomX Therapeutics's estimated revenue per employee is $441,467
  • CytomX Therapeutics's total funding is $345.4M.
  • CytomX Therapeutics's current valuation is $257.7M. (January 2022)

Employee Data

  • CytomX Therapeutics has 150 Employees.(i)
  • CytomX Therapeutics grew their employee count by -4% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company's pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit or follow us on Twitter.

keywords:Biotechnology,Healthcare,Human Resources Hr,Pharmaceuticals


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





CytomX Therapeutics's People

Senior Bioinformatics Scientist
VP Clinical Development
Executive Director, Protein Sciences
Senior Scientist II - Protein Engineering
Senior Director Process Development
Executive Assistant
Senior Research Associate
Senior Director Toxicology
SVP, Talent and Systems Development

CytomX Therapeutics News

2022-04-17 - Shareholders in CytomX Therapeutics (NASDAQ:CTMX) have lost 87%, as stock drops 10% this past week

Given that CytomX Therapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its...

2022-04-13 - CytomX Therapeutics Announces Retirement of John A. Scarlett ...

SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of...

2022-04-06 - CytomX Therapeutics, Inc. (NASDAQ:CTMX) Expected to Announce ...

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody...

2021-11-04 - CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update - Form 8-K

CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update -Initial data release from Phase 2 study of CX-2029 remains on track for fourth quarter 2021- -Initial data release from Phase 2 study of praluzatamab ravtansine (CX-2009) expected in 2022- SOUTH ...

2021-08-05 - CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today r ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

CytomX Therapeutics Funding

DateAmountRoundLead InvestorsReference
2012-08-01$41.0MBCanaan PartnersArticle
2015-01-07$20.0MCPfizer Venture InvestmentsArticle
2015-06-17$70.0MDFidelity Management & Research CompanyArticle